{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:30:52Z","timestamp":1784694652710,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12872-016-0425-x","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T06:50:22Z","timestamp":1480575022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Nicolas M.","family":"Berbenetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Mrkobrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"issue":"16","key":"425_CR1","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240\u2013327.","journal-title":"Circulation"},{"issue":"5","key":"425_CR2","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.amjopharm.2009.10.001","volume":"7","author":"JW Cheng","year":"2009","unstructured":"Cheng JW, Nayar M. A review of heart failure management in the elderly population. Am J Geriatr Pharmacother. 2009;7(5):233\u201349.","journal-title":"Am J Geriatr Pharmacother"},{"issue":"5","key":"425_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s12170-011-0184-2","volume":"5","author":"T Bhuiyan","year":"2011","unstructured":"Bhuiyan T, Maurer MS. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep. 2011;5(5):440\u20139.","journal-title":"Curr Cardiovasc Risk Rep"},{"issue":"3","key":"425_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215\u201325.","journal-title":"Eur Heart J"},{"issue":"9386","key":"425_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777\u201381.","journal-title":"Lancet"},{"issue":"19","key":"425_CR6","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JG Cleland","year":"2006","unstructured":"Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338\u201345.","journal-title":"Eur Heart J"},{"issue":"15","key":"425_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O\u2019Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT I. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383\u201392.","journal-title":"N Engl J Med"},{"issue":"16","key":"425_CR8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/eurheartj\/ehu067","volume":"35","author":"M Komajda","year":"2014","unstructured":"Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J. 2014;35(16):1022\u201332.","journal-title":"Eur Heart J"},{"key":"425_CR9","doi-asserted-by":"crossref","unstructured":"Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European Heart Journal 2012 July;33(14):1750\u20137.","DOI":"10.1093\/eurheartj\/ehr254"},{"issue":"2","key":"425_CR10","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","author":"M Gasparo de","year":"1987","unstructured":"de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J, Schmidlin J. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240(2):650\u20136.","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"425_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"14","key":"425_CR12","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321. Erratum appears in N Engl J Med. 2003 May 29;348(22):2271.","journal-title":"N Engl J Med"},{"issue":"1","key":"425_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1445-5994.1986.tb01119.x","volume":"16","author":"H Ikram","year":"1986","unstructured":"Ikram H, Webster MW, Nicholls MG, Lewis GR, Richards AM, Crozier IG. Combined spironolactone and converting-enzyme inhibitor therapy for refractory heart failure. Aust N Z J Med. 1986;16(1):61\u20133.","journal-title":"Aust N Z J Med"},{"issue":"10","key":"425_CR14","doi-asserted-by":"publisher","first-page":"02","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):02.","journal-title":"N Engl J Med"},{"issue":"6","key":"425_CR15","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67(6):1355\u201364.","journal-title":"Circ Res"},{"key":"425_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-014-0261-8","volume":"13","author":"Y Chen","year":"2015","unstructured":"Chen Y, Wang H, Lu Y, Huang X, Liao Y, Bin J. Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials. BMC Med. 2015;13:10.","journal-title":"BMC Med"},{"issue":"11","key":"425_CR17","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1345\/aph.10104","volume":"34","author":"SJ Lloyd","year":"2000","unstructured":"Lloyd SJ, Mauro VF. Spironolactone in the treatment of congestive heart failure. Ann Pharmacother. 2000;34(11):1336\u201340 [Review] [20 refs].","journal-title":"Ann Pharmacother"},{"issue":"8","key":"425_CR18","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B, Aldo-DHF I. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309(8):781\u201391.","journal-title":"JAMA"},{"issue":"5","key":"425_CR19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"8","author":"D Moher","year":"2010","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336\u201341.","journal-title":"Int J Surg"},{"issue":"7650","key":"425_CR20","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"425_CR21","unstructured":"Schwarzer G. meta: A n R package for meta-analysis. R News. 2007;7(3):40\u201345."},{"key":"425_CR22","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. [computer program]. Vienna: R Foundation for Statistical Computing; 2015. http:\/\/www.Rproject.org\/ ."},{"issue":"5","key":"425_CR23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1536\/jhj.44.681","volume":"44","author":"M Akbulut","year":"2003","unstructured":"Akbulut M, Ozbay Y, Ilkay E, Karaca I, Arslan N. Effects of spironolactone and metoprolol on QT dispersion in heart failure. Jpn Heart J. 2003;44(5):681\u201392.","journal-title":"Jpn Heart J"},{"issue":"1","key":"425_CR24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","volume":"11","author":"A Boccanelli","year":"2009","unstructured":"Boccanelli A, Mureddu GF, Cacciatore G, Clemenza F, Di LA, Gavazzi A, Porcu M, Latini R, Lucci D, Maggioni AP, Masson S, Vanasia M, de Simone G, AREA INC. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail. 2009;11(1):68\u201376.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"425_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","volume":"50","author":"AK Chan","year":"2007","unstructured":"Chan AK, Sanderson JE, Wang T, Lam W, Yip G, Wang M, Lam YY, Zhang Y, Yeung L, Wu EB, Chan WW, Wong JT, So N, Yu CM. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007;50(7):591\u20136.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"425_CR26","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","volume":"40","author":"M Cicoira","year":"2002","unstructured":"Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Marino P, Zardini P. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40(2):304\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"425_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","volume":"17","author":"A Deswal","year":"2011","unstructured":"Deswal A, Richardson P, Bozkurt B, Mann DL. Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF). J Card Fail. 2011;17(8):634\u201342.","journal-title":"J Card Fail"},{"key":"425_CR28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jacc.2009.03.066","volume":"54","author":"NC Edwards","year":"2009","unstructured":"Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol. 2009;54:505\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"425_CR29","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","volume":"13","author":"X Gao","year":"2007","unstructured":"Gao X, Peng L, Adhikari CM, Lin J, Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail. 2007;13(3):170\u20137.","journal-title":"J Card Fail"},{"issue":"31","key":"425_CR30","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"issue":"3","key":"425_CR31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1161\/CIRCHEARTFAILURE.109.906909","volume":"3","author":"JE Udelson","year":"2010","unstructured":"Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3(3):347\u201353.","journal-title":"Circ Heart Fail"},{"issue":"4","key":"425_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/MAJ.0b013e31829dd6b1","volume":"347","author":"E Vizzardi","year":"2014","unstructured":"Vizzardi E, Nodari S, Caretta G, D\u2019Aloia A, Pezzali N, Faden G, Lombardi C, Raddino R, Metra M, Dei CL. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am J Med Sci. 2014;347(4):271\u20136.","journal-title":"Am J Med Sci"},{"issue":"1","key":"425_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"5","key":"425_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith Jr SC, Svetkey LP, Taler SJ, Townsend RR, Wright Jr JT, Narva AS, Ortiz E. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507\u201320.","journal-title":"JAMA"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0425-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-016-0425-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-016-0425-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:51:42Z","timestamp":1749757902000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-016-0425-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["425"],"URL":"https:\/\/doi.org\/10.1186\/s12872-016-0425-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727055345.793527045","asserted-by":"object"}]},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12]]},"article-number":"246"}}